- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04683952
Rehabilitation With HHFNC in COPD in Nocturnal NIV
Efficacy of Exercise Training With Humified High Flow Nasal Cannula, in Patients With Chronic Obstructive Pulmonary Disease Already in Nocturnal Non-Invasive Ventilation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RECRUITMENT PHASE: A qualified physiotherapist will check patient lists daily with the aim of identifying suitable candidates for the study.
The patients will be enrolled from January 2020 till june 2021 and they will be stratified individually and randomized by a dedicated software (https://www.randomizer.org/) into two groups:
- Experimental group - Chronic Obstructive Pulmonary Disease (COPD) patients in nocturnal Non Invasive Ventilation (NIV) underwent to respiratory rehabilitation with Humidified High Flow Nasal Cannula (HHFNC) with / without Oxygen Therapy (O2), according to medical prescription;
- Control group - patients in nocturnal NIV underwent to respiratory rehabilitation without HFNC with / without O2, according to medical prescription.
Before randomization, individual clinical inclusion and exclusion criteria will be taken into account in relation to the ability of each patient to tolerate the administration of the high flow ventilation program foreseen by the study.
RUN IN PHASE: After the assessment, each patient will perform a training session prior to the cycle ergometer, during which the subject will work on the workload and the established flow. The intensity of the workload will be 60-80% of the Wmax, calculated with the Hill's formula:
Wmax = ( 0.122 x 6MWD) + (72, 683 x Height) - 117.109
(where 6MWD is the distance walked on the 6-minute walk test, and the patient's height must be expressed in meters).
NIV and HHFNC will be administered through VEMO 150 (EOVE SA. 64000 Pau - France), a device with which it is possible setting up to 4 different ventilation programs. The High Flow can be delivered, as a continuous flow through the humidified nasal cannulas, up to 60 L / min with or without additional oxygen therapy according to medical prescription. The patients of the experimental group will be trained with the most adequate continuous flow, in a range between 20 and 60 L/min, according to the maximum flow supported by the patient.
FOLLOW UP PHASE: Outpatient rehabilitation will be performed in 3 cycles, each cycle in 40-minute sessions, 3 times a week. Each session starts with the cycle ergometer with a 5-minute warm-up to an intensity of 0 watts, continues with a 30-minute resistance training phase at a continuous target intensity (60-80% Wmax), then a warm-down of 5 minutes at an intensity of 0 watts.
The rehabilitation will be followed by a three-month washout period, for 3 cycles.
MEASUREMENTS: We have identified four periods to evaluate gas exchange, Forced expiratory volume in one second (FEV1) and respiratory muscle strength, dyspnea, exercise capacity, the presence of obstructive/central sleep apnea, prediction of mortality, activities of daily life, the impact of the disease and the quality of life.
These four periods are:
- T0: baseline;
- T1: at the end of the first rehabilitation cycle;
- T2: at the end of the second rehabilitation cycle;
- T3: at the end of the third rehabilitation cycle.
At the beginning of the study, demographics and clinical characteristics of eligible study participants will be collected.
Patients will be evaluated for:
- Blood gas analysis (BGA) in T0, T1, T2, T3;
- Spirometry: Forced Vital Capacity (FVC), FEV1 and FEV1/FEVC% in T0, T3;
- Questionnaire of the British Medical Research Council (MRC) modified, in T0, T1, T2, T3;
- Basic / Transition Dyspnea Index (BDI / TDI), in T0, T1, T2, T3;
- 6 Minute Walking Distance (6MWD) with / without oxygen therapy, according to the medical prescription during the effort, in T0, T1, T2, T3;
- COPD Assessment Test (CAT) in T0, T1, T2, T3;
- Night time Polygraph to detect apnea/hypopnea, in T0, T3 ;
- BODE INDEX (where BODE means body mass index, obstruction of air flow, dyspnoea and exercise capacity), in order to estimate the probability of survival, in T0, T1, T2, T3;
- Saint George Respiratory Questionnaire (SGRQ) to investigate the quality of life in T0 and T3;
- Evaluation of the perception of muscle fatigue and dyspnea (Borg RPE) and Visual Analogue Scale (VAS) each session.
During training, and the run-in phase, the physiotherapist will take note of FiO2 and of the dyspnea at the beginning and end of the session through VAS / BORG and again when the patient will be evaluated in 6MWD).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20148
- Recruiting
- IRCCS Santa Maria Nascente, Fondazione Don Carlo Gnocchi
-
Contact:
- Paolo Banfi, MD
- Phone Number: 0039 0240308812
- Email: pabanfi@dongnocchi.it
-
Contact:
- Laila Di Pietro, RT
- Phone Number: 0039 024038570
- Email: ldipietro@dongnocchi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Chronic Obstructive Pulmonary Disease (post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) <0.7) ;
- Nocturnal Non Invasive Ventilation (NIV) prescription according to ATS/ERS guidelines with or without long-term oxygen therapy;
- Clinical stability (no exacerbation and no changing in respiratory drugs in the last 7 days);
Exclusion Criteria:
- Orthopedic or neurological pathologies that limit physical performance;
- Cognitive impairment (Mini-Mental State Examination <24);
- Advanced heart disease, pulmonary fibrosis, participation in other clinical studies in the six months preceding the start of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Rehabilitation with HHFNC
15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. |
The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
Other Names:
|
|
Active Comparator: Control Group rehabilitation without HHFNC
15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC). The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months. |
The control group will perform exercise training in spontaneous breathing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in 6MWD
Time Frame: "Baseline ( pre-intervention)" and "Immediately after the intervention".
|
The first outcome we expect to find is a change in the distance at 6-Minute Walking Distance (6MWD).
|
"Baseline ( pre-intervention)" and "Immediately after the intervention".
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Exacerbations, GP visits and admission to ED and ICU
Time Frame: Through study completion, an average of 1 year.
|
The second outcome is change of COPD exacerbation as admission to the Intensive Care Unit (ICU), to the admission to the ED with/without hospitalization, Generale Practitioner (GP) unplanned visits.
|
Through study completion, an average of 1 year.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Points at Saint George Respiratory Questionnaire (SGRQ)
Time Frame: "Baseline ( pre-intervention)" and "Immediately after the intervention".
|
The third outcome concerns the quality of life for which we expect changes in the results at the Saint George Respiratory Questionnaire (SGRQ) in the experimental group.
SGRQ: from 0 (no health impairment) to 100 (maximum health impairment).
|
"Baseline ( pre-intervention)" and "Immediately after the intervention".
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paolo Banfi, MD, Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria Nascente
- Study Chair: Laila Di Pietro, RT, Fondazione Don C. Gnocchi - I.R.C.C.S. Santa Maria Nascente
Publications and helpful links
General Publications
- Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol. 2014 Aug 7;14:66. doi: 10.1186/1471-2253-14-66. eCollection 2014.
- Stephan F, Berard L, Rezaiguia-Delclaux S, Amaru P; BiPOP Study Group. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017 Sep;62(9):1193-1202. doi: 10.4187/respcare.05473. Epub 2017 Aug 14.
- Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008 Sep;89(9):1782-7. doi: 10.1016/j.apmr.2008.01.020.
- Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M, Gonzalez-Bermejo J, Hart N, Lujan M, Nasilowski J, Nava S, Pepin JL, Pisani L, Storre JH, Wijkstra P, Tonia T, Boyd J, Scala R, Windisch W. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. Print 2019 Sep.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDG_HFNC_COPD_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Exercise training with Humified High Flow Nasal Cannula
-
Rush University Medical CenterThe University of Texas Health Science Center, Houston; Medical College of... and other collaboratorsRecruitingObesity, Morbid | Extubation FailureUnited States, Mexico
-
Zhejiang UniversityRecruitingGastric Cancer | Esophageal Cancer | Hypoxemia | Morbidly Obese PatientsChina
-
Aga Khan University Hospital, PakistanUnknownApneic Oxygenation
-
University of MiamiAmerican Thoracic SocietyRecruiting
-
Hospital Clinic of BarcelonaUnknownPatient Population Submitted to ERCPSpain
-
Wenxian LiRecruitingDifficult Airway | Awake Tracheal IntubationChina
-
Kuopio University HospitalCentral Finland Hospital District; Mikkeli Central Hospital; Siun soteRecruiting
-
Montefiore Medical CenterCompletedMorbid Obesity | Noninvasive Ventilation | Deep SedationUnited States
-
Hospital do CoracaoMinistry of Health, Brazil; Berry ConsultantsCompletedRespiratory Failure | Respiratory InsufficiencyBrazil
-
Samsung Medical CenterFisher and Paykel HealthcareCompletedAcute Respiratory FailureKorea, Republic of